Abstract 2894: NTX-452: a non-covalent, potent, selective and highly efficacious WRN inhibitor with best-in-class potential for the treatment of MSI-H tumorsRobert Svensson, Peter J. Tummino, Justin A. Caravella et al.|Cancer Research|2025Cited by 5
Abstract 589: Discovery of NTX-001, a potent Cbl-b inhibitor with antitumor activity in syngeneic modelsFred Csibi-Levin, David Ciccone, Silvana Leit et al.|Cancer Research|2022Cited by 1
356 (PB344): Preclinical characterization of NTX-452, a potent, selective and highly efficacious WRN inhibitor for the treatment of MSI-H tumorsScott Boiko, Robert Svensson, Di Li et al.|European Journal of Cancer|2024Cited by 0